Novartis breaks ground in Russia; Lupin eyes bigger margins long term;

@FiercePharma: Forest fights back against Icahn in filing. Article | Follow @FiercePharma

> Novartis has started construction of its new St. Petersburg manufacturing plant, the centrepiece of its planned, $500 million five-year investment into Russia. Article

> Lupin may find it tough to improve its operating margin this fiscal year, but the Indian generics maker's profitability is expected to jump in a couple of years, helped mainly by the launch of several lucrative products in the U.S. Item

> European regulators have followed FDA in granting marketing authorization for Bristol-Myers Squibb's Nulojix, which aims to prevent kidney transplant patients rejecting their new organ. Report

> Eli Lilly and Amylin Pharmaceuticals may put their disagreements over marketing pacts to one side temporarily after European regulators gave the thumbs-up to their once-weekly diabetes drug Bydureon. Story

> A recent meeting with Pfizer managers has confirmed optimism that the drugmaker will not be abandoning Groton, CT, completely, chamber officials said. News

> Sun Pharma won the FDA nod for its generic version of GlaxoSmithKline's migraine drug Imitrex. Item

Biotech News

@FierceBiotech: Abbott inks $470M pact for Biotest's Ph2 RA antibody program. Story | Follow @FierceBiotech

@JohnCFierce: This Tesaro deal reminds me of the success Clovis has had in raising big $$$. Experience+clear strategy in cancer is appealing to investors. | Follow @JohnCFierce

> FDA's safety concerns force Merck KGaA to kill cladribine MS program. Report

> FDA experts reject Novartis gout drug. Story

Drug Delivery News

> FDA looking for advice on regulating nanotech. Story

> Europe's Bydureon approval is victory for Alkermes. Report

> J&J drops Cypher drug-coated stents in more bad news for SurModics. Piece

> Body's blood-clotting machinery harnessed against cancer. Item

> Neural probe to include microchannels to deliver drugs to tinnitus sufferers. Article

> NIST to test the value of gold in drug-delivering nanoparticles. Article

Medical Device News

> Medtronic faces Senate scrutiny over Infuse. Article

> 3M accuses Porton CEO of blackmail. News

> GAO: FDA doesn't oversee device recalls properly. Article

> AZ, Dentsply reach deal on Astra Tech. Story

> Mauna Kea looks to raise $67.7M in IPO. Report

> Mendor raises $11.7M in Series B. Item

And Finally... To build up its medical device business in rural parts of India and China, Johnson & Johnson is focusing heavily on a strategy that involves simplifying things. Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.